You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. The Development and Systematic Evaluation of an AI-Assisted Just-in-Time-Adaptive-Intervention for Improving Child Mental Health

    SBC: Colliga Apps Corp.            Topic: 104

    PROJECT SUMMARY/ABSTRACT Early childhood mental health problems constitute a significant public health concern with wide-ranging impacts on functioning both concurrently and later in life. Although childhood mental health is influenced by a variety of factors, the quality of relationships with caregivers plays a critical role. Critical, coercive, and conflictual parent- child interactions have bee ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?

    SBC: Mabloc, LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to approximately ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise

    SBC: Myolyn, LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT Lack of exercise is a major cause of secondary health conditions, especially for people with paralysis, for whom participation in physical activity is especially difficult. Hybrid functional electrical stimulation (H- FES) exercise enables vigorous, total body physical activity for people with paralysis. However, existing H-FES devices are neither affordable nor accessible ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. STING Activators as Therapy for Cancer

    SBC: STINGINN, LLC            Topic: 101

    PROJECT SUMMARY The ability of dying cells to activate antigen presenting cells (APCs) is carefully controlled to avoid unwarranted inflammatory responses. Thus, tumor cells avoid aggravating APCs by efficiently simulating regular dying cells which following phagocytosis do not trigger inflammatory responses required for efficient cytotoxic T lymphocyte (CTL) priming. However, dying tumor cells co ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most proposed AD disease modifying therapies have focused on strategies that reduce brain Aβ/amyloid or tau pathological accumulation. However, such approaches have been unsuccessful in late stage AD clin ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government